Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1314-1321

  Pendyala, Lakshmi ^a   Creaven, Patrick J ^a   Schwartz, Gary ^a   Meropol, Neal J ^a,b   Bolanowska Higdon, Wanda ^a   Zdanowicz, Joseph ^a   Murphy, Michael ^a   Perez, Raymond ^a,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GLUTATHIONE PEROXIDASE; IFOSFAMIDE; MESNA;

ADULT; AGED; AMINO ACID METABOLISM; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; LEUKOCYTE; MALE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACETALDEHYDE; ANTINEOPLASTIC AGENTS, ALKYLATING; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HOMOCYSTEINE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; LEUKOCYTES; MESNA; NEOPLASMS; OXIDATION-REDUCTION; PROTECTIVE AGENTS; SULFHYDRYL COMPOUNDS;

EID: 0034089158     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Deleve, L. D., and Kaplowitz, N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol. Then. 52: 287-305, 1991.
2. Tew, K. D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res., 54: 4313-4320, 1994.
3. Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., and Ozols, R. F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47: 414-418, 1987.
4. Bailey, H. H., Gipp, J. J., Ripple, M., Wilding, G., and Mulcahy, R. T. Increase in γ-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res., 52: 5115-5118, 1992.
5. Hamaguchi, K., Godwin, A. K., Yakushiji, M., O'Dwyer, P. J., Ozols, R. F., and Hamilton, T. C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res., 53: 5225-5232, 1993.
6. Rairkar, A., and Ali-Osman, F. Modulation of DNA ligase activities in a BCNU and cisplatin resistant human malignant astrocytoma cell line by glutathione depletion. Proc. Am. Assoc. Cancer Res., 33: 7, 1992.
7. Ali-Osman, F., and Rairkar, A. Alterations in DNA polymerases α, β, and δ in human brain tumor cells after glutathione depletion. Proc. Am. Assoc. Cancer Res., 33: 497, 1992.
8. Chen, G., and Zeller, W. J. Augmentation of cisplatin cytotoxicity in vivo by D,L-buthionine sulfoximine in DDP sensitive and resistant rat ovarian tumors and its relation to DNA interstrand cross links. Anticancer Res., 11: 2231-2238, 1991.
9. Lai, G., Ozols, R., Young, R., and Hamilton, T. Effect of glutathione on DNA repair in cisplatin resistant human ovarian cancer cell lines. J. Natl. Cancer Inst., 81: 535-539, 1989.
10. Ishikawa, T., and Ali-Osman, F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem., 268: 20116-20125, 1993.
11. Ishikawa, T., Wright, C. D., and Ishizuka, H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J. Biol. Chem., 269: 29085-29093, 1994.
12. Zaman, G. J. R., Lankelma, J., Tellingen, O. V., Beijnen, J., Dekker, H., Paulusma, C., Oude Elferink, R. P. J., Bass, F., and Borst, P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA, 92: 7690-7694, 1995.
13. Vanhoefer, U., Cao, S. S., Minderman, H., Toth, K., Skenderis, B. S., Slovak, M. L., and Rustum, Y. M. D,L-Buthionine-(S,R-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein expressing tumors. Clin. Cancer Res., 2: 1961-1968, 1996.
14. Voehringer, D. W., McConkey, D. J., McDonnel, T. J., Brisbay, S., and Meyn, R. E. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc. Natl. Acad. Sci. USA, 95: 2956-2960, 1998.
15. Mistry, P., Loh, S. Y., Kelland, L. R., and Harrap, K. R. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Int. J. Cancer, 55: 848-856, 1993.
16. Meijer, C., Mulder, N. H., Timmer-Bosscha, H., Wluiter, W. J., Meersma, G. J., and de Vries, E. G. E. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res., 52: 6885-6889, 1992.
17. Ozols, R. F., Louie, K. G., Plowman, J., Behrens, B. C., Fine, R. F., Dykes, D., and Hamilton, T. C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol., 36: 147-153, 1987.
18. O'Dwyer, P. J., Hamilton, T. C., Young, R. C., Lacreta, F. P., Carp, N., Tew, K. D., Padavic, R., Comis, R. L., and Ozols, R. F. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J. Natl. Cancer Inst., 84: 264-267, 1992.
19. Bailey, H. H., Mulcahy, R. T., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Tombes, M. B., Wilding, G., Pomplun, M., and Spriggs, D. R. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J. Clin. Oncol., 72: 194-205, 1994.
20. O'Dwyer, P. J., Hamilton, T. C., Lacreta, F. P., Gallo, J. M., Kilpatrick, D., Halbherr, T., Brennan, J., Bookman, M. A., Hoffman, J., Young, R. C., Comis, R. L., and Ozols, R. F. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol., 14: 249-256, 1996.
21. Lind, M. J., McGown, A. T., Hadfield, J. A., Thatcher, N., Crowther, D., and Fox, B. W. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem. Pharmacol., 36: 1835-1840, 1989.
22. Lauterburg, B. H., Nguyen, T., Hartmann, B., Junker, E., Kupfer, A., and Cerny, T. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother. Pharmacol., 35: 132-136, 1994.
23. Stofer-Vogel, B., Kupfer, C. A., Junker, E., and Lauterburg, B. H. Depletion of circulating cyst(e)ine by oral and intravenous mesna. Br. J. Cancer, 68: 590-593, 1993.
24. Malik, I. A., Mehboobali, N., and Iqbal, M. P. Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer. Cancer Chemother. Pharmacol., 39: 561-565, 1997.
25. Calvert, A. H., Newell, D. R., and Gumbrell, L. A. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 1748-1756, 1989.
26. Burgunder, J. M., Varriale, A., and Lauterburg, B. H. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur. J. Clin. Pharmacol., 36: 127-131, 1989.
27. Anderson, M. E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol., 113: 548-555, 1985.
28. Pendyala, L., Creaven, P. J., Perez, R., Zdanowicz, J. R., and Raghavan, D. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother. Pharmacol., 36: 271-278, 1995.
29. Pendyala, L., and Creaven, P. J. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a Phase I trial. Cancer Epidemiol. Biomark. Prev., 4: 245-251, 1995.
30. Fahey, R. C., and Newton, G. L. Determination of low molecular weight thiols using monobromobimane fluorescent labelling and high performance liquid chromatography. Methods Enzymol., 143: 85-96, 1987.
31. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
32. Kaijser, G. P., Beijnen, J. H., Jeunink, E. L., Bult, A., Keizer, H. J., de Kraker, J., and Underberg, W. J. M. Determination of chloroacetaldehyde, a metabolite of oxazaphoshphorine cytostatic drugs, in plasma. J. Chromatogr., 614: 253-259, 1993.
33. Meister, A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther., 51: 155-194, 1991.
34. Dirven, H. A. A. M., Megens, L., Oudshoorn, M. J., Dingermanse, M. A., van Ommen, B., and van Bladeren, P. J. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem. Res. Toxicol., 8: 979-986, 1995.
35. Buolamwini, J. K., and Ali-Osman, F. Flexible docking of 4-hydroxyifosfamide in the putative H-site of allelo-polymorphic human glutathione-S-transferase π (GST-π) proteins. Proc. Am. Assoc. Cancer Res., 40: 674, 1999.
36. Ali-Osman, F., Akande, O., Antoun, G., Mao, J., and Buolamwini, J. K. Molecular cloning, characterization and expression in Escherichia coli of full length cDNAs of three human glutathione-S-transferase π gene variants. J. Biol. Chem., 272: 10004-10012, 1997.
37. Hu, X., Xia, H., Srivatsava, S. K., Herzog, C., Awasthi, Y. C., Ji, X., Zimniak, P., and Singh, S. V. Activity of four allelic forms of glutathione-S-transferase hGSTP-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem. Biophys. Res. Commun., 238: 397-402, 1997.